^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

Excerpt:
...Mutated P53 or Ras pathway genes (CBL, NRAS, KRAS, NF1, PTPN1) or DNMT 3a or ASXL1 or RUNX1 3....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Excerpt:
...- Prescence of mutation in the RAS pathway including NRAS, KRAS, PTPN11, CBL, NF1, RIT1, FLT3, and KIT...
Trial ID:
Less C2 evidence
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

837 Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia

Published date:
11/03/2022
Excerpt:
In this study, we aimed to evaluate the efficacy of VEN combined with hypomethylating agents (HMA) and identify the potentially predictive factors for response in R/R AML....Mutations in IDH1/2, NPM1 and ASXL1 predicted superior response to VEN-based therapy (CRc: 78.3%, 70.8% and 65.0%, respectively), while mutations in active signaling, such as FLT3-ITD, K/NRAS predicted inferior response (CRc: 29.0% and 28.6%).
Secondary therapy:
Hypomethylating agent
DOI:
https://doi.org/10.1182/blood-2022-158762
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

537 Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy

Published date:
11/03/2022
Excerpt:
Patients with AML who received front-line Ven+HMA outside clinical trials at the Mayo Clinic between 2018 and 2020 were retrospectively recruited...The current study identifies presence of TP53 and K/NRAS mutations as predictors of inferior survival in patients with AML relapsed or refractory to front-line Ven+HMA.
Secondary therapy:
Hypomethylating agent
DOI:
https://doi.org/10.1182/blood-2022-165491
Evidence Level:
Resistant: C3 – Early Trials
Title:

Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia

Published date:
10/25/2022
Excerpt:
With a median follow-up of 11.2 (95%CI, 7.2-14.8) months, 1- and 2-year overall survival were 46.9% (95% CI, 37.8%-58.1%) and 38.9% (95% CI, 28.7%-52.9%), respectively…Mutations in IDH1/2, NPM1, ASXL1 and chromatin-cohesin genes predicted superior response to VEN-based therapy, whereas mutations in active signaling genes such as FLT3-ITD and K/NRAS predicted inferior response...VEN combined with HMA was effective with R/R AML patients, and the response to treatment was associated with genetic characteristics.
Secondary therapy:
Hypomethylating agent
DOI:
10.1111/joim.13581
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Published date:
03/09/2021
Excerpt:
...86 patients with RR-AML who were treated with venetoclax combinations...Azacitidine + venetoclax resulted in higher response rates compared with low-dose cytarabine + venetoclax...Mutations in NPM1 were associated with higher response rates, whereas adverse cytogenetics and mutations in TP53, KRAS/NRAS, and SF3B1 were associated with worse OS.
DOI:
10.1182/bloodadvances.2020003734
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia

Published date:
08/18/2020
Excerpt:
By integrating clinical characteristics, exome and RNA sequencing, and inhibitor data from primary AML patient samples, we determined that myelomonocytic leukemia, upregulation of BCL2A1 and CLEC7A, as well as mutations of PTPN11 and KRAS conferred resistance to venetoclax and multiple venetoclax combinations.
DOI:
10.1038/s43018-020-0103-x
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia

Published date:
11/06/2019
Excerpt:
DEC10-VEN is an effective regimen for AML. Addition of FLT3i to DEC10-VEN was safe and may improve upon responses in FLT3mut pts. Mutations in NPM1 and DNA methylation pathways were associated with more durable responses while mutations in ASXL1, RAS and TP53 were associated with refractory disease or relapse.
DOI:
https://doi.org/10.1182/blood-2019-128547
Trial ID:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment

Published date:
11/01/2018
Excerpt:
...we observed that AML samples harboring PML-RARA translocations, WT1, and FLT3 with IDH1 mutations are more sensitive to venetoclax, and samples with TET2, KRAS, PTPN11 and SF3B1 mutations are more resistant.
DOI:
https://doi.org/10.1182/blood-2018-175